Highlights Personalis, Inc.

Equities

PSNL

US71535D1063

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
1.54 ^USD	-3.75%		+21.74%	-26.67%

Apr. 30	Lake Street Starts Personalis With Buy Rating, $4 Price Target	MT
Mar. 26	Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring	Mar. 26	CI
Personalis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Earnings Flash (PSNL) PERSONALIS Reports Q4 Revenue $19.7M, vs. Street Est of $19.3M	Feb. 28	MT
Personalis, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024	Feb. 28	CI
Personalis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Personalis, Inc. and ClearNote Health, Inc. Announce Partnership to Advance Epigenomic Technology	Jan. 30	CI
Personalis Announces Medicare Coverage for Next Dx(R) Comprehensive Genomic Tumor Profiling Assay	Jan. 16	CI
Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	Jan. 05	CI
Personalis, Tempus Labs to Collaborate on NeXT Personal Dx Detection Test	Nov. 28	MT
Personalis and Tempus Enter into Strategic Collaboration to Advance Cancer Testing	Nov. 28	CI
Myriad Genetics, Inc. and Personalis, Inc. Partner to Market Solutions to Pharma Customers	Nov. 16	CI
Personalis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Earnings Flash (PSNL) PERSONALIS Posts Q3 Revenue $18.2M, vs. Street Est of $17M	Nov. 07	MT
Personalis, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023	Nov. 07	CI
Personalis, Inc. Revises Earnings Guidance for the Full Year 2023	Nov. 07	CI
Personalis, Inc. Launches NeXT Personal DX for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer	23-10-26	CI
Personalis, Inc. Announces the Presentation of Initial Findings from Its Work with the Tracerx Lung Cancer Study	23-10-21	CI
Personalis Receives New Task Order Under US Department of Veterans Affairs Contract	23-08-28	MT
Personalis, Inc. Receives New Task Order Under Its Contract with the U.S. Department of Veterans Affair	23-08-28	CI
Personalis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Personalis, Inc.

Equities

PSNL

US71535D1063

Highlights

Filters